Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants - 05/08/23
Highlights |
• | Monoclonal antibody resistant SARS-CoV-2 variants pose a unique challenge. |
• | There is high risk of breakthrough infection in the era of antibody resistance. |
• | Cancer patients are at risk for viral rebound and disease progression. |
Plan
Vol 87 - N° 3
P. 282-285 - septembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.